AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial.
Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative.
Patients with schizophrenia discharged on an LAI antipsychotic had significantly lower 30-day psychiatric readmission rates than those sent home with an oral antipsychotic.
Adults with resistant schizophrenia have significant gut microbiome differences vs their counterparts who respond to treatment, a new finding that may be driven by clozapine treatment.